ImExHS Limited (AU:IME)
ASX:IME
Want to see AU:IME full AI Analyst Report?
IME Stock Chart & Stats
AU$0.40
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.40
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.22 - AU$0.47
Previous CloseN/A
Volume202.98K
Average Volume (3M)41.77K
Market Cap
AU$20.82M
Enterprise ValueAU$18.08M
Total Cash (Recent Filing)AU$3.30M
Total Debt (Recent Filing)AU$566.32K
Price to Earnings (P/E)44.2
Beta0.20
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding54,070,730
10 Day Avg. Volume23,052
30 Day Avg. Volume41,775
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)1.29
Price to Sales (P/S)0.71
P/FCF Ratio83.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.50Price Target Upside25.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$32.60M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthSustained acceleration to 10% revenue growth demonstrates expanding adoption of ImExHS's cloud and AI imaging suite. Durable top-line momentum supports scale economics, enlarges addressable market penetration, and underpins recurring subscription revenue and multi-year contracts over the next 2-6 months.
Very Low LeverageA conservatively levered balance sheet with a 0.04 debt-to-equity ratio gives ImExHS durable financial flexibility. Low debt reduces refinancing risk, allows funding for product development or strategic partnerships, and supports resilience versus cyclical healthcare IT spending over the medium term.
Turnaround To Positive Cash FlowMoving to positive operating and free cash flow signals improving cash conversion and internal funding capacity. This durable shift reduces reliance on external capital, enables iterative product investment and customer support, and strengthens the company’s ability to execute its SaaS growth strategy.
Bears Say
Persistent LossesOngoing net losses and negative operating margins constrain ImExHS's ability to generate shareholder returns and reinvest internally. Over a 2-6 month horizon this limits strategic optionality, raises dependency on capital markets for scaling, and makes achieving sustainable profitability a key structural challenge.
Sharp Gross Margin DeclineA material drop in gross margin suggests pricing pressure or rising delivery costs that erode the core economics of the Hiruko platform. If structural, this undermines long-term margin sustainability, reduces incremental profitability as revenue scales, and pressures operating leverage over months ahead.
Cash Flow VolatilityDespite recent positive cash flow, historically inconsistent conversion and swings expose the business to funding and operational timing risk. This structural volatility complicates budgeting, weakens confidence in repeatable free cash generation, and could force precautionary capital raises.
ImExHS Limited News
IME FAQ
What was ImExHS Limited’s price range in the past 12 months?
ImExHS Limited lowest share price was AU$0.22 and its highest was AU$0.47 in the past 12 months.
What is ImExHS Limited’s market cap?
ImExHS Limited’s market cap is AU$20.82M.
When is ImExHS Limited’s upcoming earnings report date?
ImExHS Limited’s upcoming earnings report date is Aug 31, 2026 which is in 128 days.
How were ImExHS Limited’s earnings last quarter?
ImExHS Limited released its earnings results on Feb 26, 2026. The company reported AU$0.002 earnings per share for the quarter, beating the consensus estimate of -AU$0.015 by AU$0.017.
Is ImExHS Limited overvalued?
According to Wall Street analysts ImExHS Limited’s price is currently Undervalued.
Does ImExHS Limited pay dividends?
ImExHS Limited does not currently pay dividends.
What is ImExHS Limited’s EPS estimate?
ImExHS Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImExHS Limited have?
ImExHS Limited has 54,070,730 shares outstanding.
What happened to ImExHS Limited’s price movement after its last earnings report?
ImExHS Limited reported an EPS of AU$0.002 in its last earnings report, beating expectations of -AU$0.015. Following the earnings report the stock price went up 9.756%.
Which hedge fund is a major shareholder of ImExHS Limited?
Currently, no hedge funds are holding shares in AU:IME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImExHS Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.50 (25.00% Upside)
AU$0.50 (25.00% Upside)
Blogger Sentiment
Bullish
AU:IME Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.55%
12-Months-Change
Fundamentals
Return on Equity
-19.01%
Trailing 12-Months
Asset Growth
8.81%
Trailing 12-Months
Company Description
ImExHS Limited
ImExHS Limited offers cloud-based medical imaging solutions in Australia and internationally. It offers a medical imaging software that is focused on the development and sale of modular imaging systems, which include information systems for radiology, cardiology, and pathology, as well as a picture archiving and communications system. The company's solutions include AQUILA, a radiology software solution; ALULA, a pathology software solution; Antero, a cardiology software solution; and STELLA.I, a set of artificial intelligence tools in the cloud that support specialists in the diagnosis. It also provides outsourced radiology services for hospitals and other establishments, as well as teleradiology services. The company was incorporated in 2001 and is based in Mascot, Australia.
IME Stock 12 Month Forecast
Average Price Target
AU$0.50
▲(25.00% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
PainChek Ltd
―
Options Prices
Currently, No data available
---